Unusual 11 Mid-Day Movers 10/10: (EGAS) (MCUR) (TSRO) Higher; (TWTR) (TWLO) (MYGN) Lower
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Macrocure Ltd. (Nasdaq: MCUR) 34.3% HIGHER; Leap Therapeutics, Inc. announced the presentation of top-line data from its clinical trial of DKN-01 combination therapy in patients with cholangiocarcinoma at the European Society for Medical Oncology 2016 Congress (ESMO 2016) in Copenhagen, Denmark. Leap has signed a Merger Agreement with Macrocure Ltd.
TESARO, Inc. (Nasdaq: TSRO) 22.9% HIGHER; Tesaro and ENGOT, the European Network for Gynaecological Oncological Trial groups, announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr. Mansoor Raza Mirza, M.D., Medical Director of the Nordic Society of Gynecologic Oncology (NSGO) and principal investigator on the ENGOT-OV16/NOVA trial.
MobileIron (Nasdaq: MOBL) 20.0% HIGHER; raised guidance for the third quarter of the fiscal year 2016 ended September 30, 2016. Gross billings for the quarter are expected to be in the range of $46.5-$47.5 million, above the company's previous guidance of $43-$45 million.
Intellipharmaceutics International Inc. (Nasdaq: IPCI) 18.8% HIGHER; announced it received tentative approval from the U.S. Food and Drug Administration (FDA) for the Company's abbreviated new drug application (ANDA) for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths. The Company's tentatively-approved product is a generic equivalent for the corresponding strengths of the branded product Seroquel XR® sold in the United States by Astra Zeneca Pharmaceuticals LP
Mazor Robotics Ltd. (Nasdaq: MZOR) 15.3% HIGHER; announced that it received purchase orders for 25 systems during the third quarter ended September 30, 2016 including pre-launch orders for the recently unveiled Mazor X, a transformative guidance platform for spine surgeries. The Mazor X will be commercially launched at the North American Spine Society (NASS) annual meeting in Boston, MA October 26-29.
Primo Water Corporation (Nasdaq: PRMW) 14.1% HIGHER; Primo Water and Glacier Water Services, Inc., a leading provider of high-quality drinking water dispensed to consumers through self-service refill water machines, today announced that they have executed a definitive merger agreement pursuant to which Primo will acquire all outstanding shares of Glacier.
Twitter's (NYSE: TWTR) 13.4% LOWER; lower following news that that company's sale process is almost dead as top bidders lose interest amid pressure from investors.
Twilio (NYSE: TWLO) 11.2% LOWER; filed a registration with the U.S. SEC to offer up to $400 million of its common stock.
Myriad Genetics, Inc. (Nasdaq: MYGN) 10.2% LOWER; announced that its myChoice HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone. The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO.
Bristol-Myers Squibb Company (NYSE: BMY) 9.8% LOWER; announced new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to investigator’s choice of therapy (methotrexate, docetaxel or cetuximab). Outcome assessments showed Opdivo stabilized patients’ symptoms and functioning, including physical, role and social functioning across three separate instruments.
Havertys (NYSE: HVT) 8.8% LOWER; Raymond James downgraded Havertys from Strong Buy to Market Perform.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Community Health Systems (CYH) Prelim. Q3 Results Fall Short of Consensus
- Aeterna Zentaris (AEZS) Announces $7.56M Common Stock, Warrants Registered Direct Offering
- ReWalk Robotics (RWLK) Prices 3.25M Unit Offering for Proceeds of ~$12.2M
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesRaymond James, First Reserve Corporation, Twitter, Unusual 11 Mid-Day Movers, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!